An MTT assay revealed that knockdown of SNHG7 facilitated drug sensitivity of breast cancer cells, but nevertheless, the inductive effect of SNHG7 inhibition on drug sensitivity of breast cancer cells was patently abolished by miR-34a downregulation (Figures 5B–D). The gene discussed is SNHG7; the disease is breast carcinoma.